Skip to Main content
  • Select Condition
    • Previously Untreated CLL/SLL
    • Previously Treated CLL/SLL
    • AML
  • Medication Guide
  • Prescribing Information
  • Safety Information
  • HEALTHCARE PROFESSIONAL SITE
VENCLEXTA® (venetoclax tablets)
  • VENCLEXTA® (venetoclax tablets)
  • Previously Untreated CLL/SLL
  • Previously Treated CLL/SLL
  • AML
  • HEALTHCARE PROFESSIONAL SITE
  • SAFETY
  • Get VENCLEXTA treatment support:
    • (844) 926-6727
    • Sign up for THE VEN ZONE

Get VENCLEXTA treatment support: (844) 926-6727, M–F, 7am–7pm CST  |  Sign up for THE VEN ZONE

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
    • are 75 years of age or older, or
    • have other medical conditions that prevent the use of standard chemotherapy.

It is not known if VENCLEXTA is safe and effective in children.

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS.
You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do
blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA.
It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness,
or muscle or joint pain.

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose,
on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.

Who should not take VENCLEXTA?

Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.

  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
  • Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

  • have kidney or liver problems.
  • have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
  • have a history of high uric acid levels in your blood or gout.
  • are scheduled to receive a vaccine. You should not receive a “live vaccine” before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
  • are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA, and you should use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA. If you become pregnant or think you are pregnant, tell your healthcare provider right away.
  • are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk.
    Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.

What should I avoid while taking VENCLEXTA?

You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

  • Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA and may pause dosing.
  • Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.

Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.

US-VENA-210260


Please see full Prescribing Information, including Medication Guide.

 

  • Site Map
  • Terms and Conditions
  • Accessibility Statement
  • Contact Us
  • Terms of Use
  • Privacy Notice
  • Cookies Settings
  • Your Privacy Choices

© 2023 AbbVie and Genentech USA, Inc. All rights reserved.
VENCLEXTA® and its design are registered trademarks of AbbVie Inc.
GAZYVA® and its design are registered trademarks of Genentech, Inc.
This site is intended for US residents only.

genentech
abbvie
venclexta

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for US healthcare professionals only. Click “Continue” if you are a healthcare professional.

Cancel
Continue

(US-VEN-220153)

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for US healthcare professionals only. Click “Continue” if you are a healthcare professional.

Cancel
Continue

(US-VEN-220153)




Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie and Genentech, Inc. Website

You are leaving the VENCLEXTA (venetoclax) site and connecting to a site that is not under the control of AbbVie or Genentech, Inc. AbbVie and Genentech, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie and Genentech, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie or Genentech, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie and Genentech, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie or Genentech, Inc.

Do you wish to leave this site?

No
Yes

Leaving AbbVie Inc. and Genentech USA, Inc. Website

You are leaving the VENCLEXTA® (venetoclax) site and connecting to a site that is not under the control of AbbVie Inc. or Genentech USA, Inc. AbbVie Inc. and Genentech USA, Inc. are not responsible for the contents of any such site or any further links from such site. AbbVie Inc. and Genentech USA, Inc. are providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie Inc. or Genentech USA, Inc. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie Inc. and Genentech USA, Inc. have no responsibility.

Conversely, the presence of this link does not imply the linked site’s endorsement of VENCLEXTA or AbbVie Inc. or Genentech USA, Inc.

Do you wish to leave this site?

No
Yes

You are leaving an AbbVie hosted website.

You are leaving the AbbVie website and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the content of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. 

Conversely, the presence of this link does not imply the linked site’s endorsement of AbbVie.

Do you wish to leave this site?

No
Yes

US-VEN-220153 - WoL

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment,

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who:

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment,

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who:

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Uses

VENCLEXTA is a prescription medicine used:

  • to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
    • are 75 years of age or older, or
    • have other medical conditions that prevent the use of standard chemotherapy.

It is not known if VENCLEXTA is safe and effective in children.

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS.
You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do
blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA.
It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness,
or muscle or joint pain.

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose,
on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.

Who should not take VENCLEXTA?

Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.

  • Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
  • Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

  • have kidney or liver problems.
  • have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
  • have a history of high uric acid levels in your blood or gout.
  • are scheduled to receive a vaccine. You should not receive a “live vaccine” before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
  • are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA, and you should use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA. If you become pregnant or think you are pregnant, tell your healthcare provider right away.
  • are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk.
    Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.

What should I avoid while taking VENCLEXTA?

You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

  • Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA and may pause dosing.
  • Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.

Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.

US-VENA-210260